Definition of a family of tissue-protective cytokines using functional cluster analysis: A proof-of-concept study

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Mengozzi, Manuela ^a   Ermilov, Peter ^a   Annenkov, Alexander ^b   Ghezzi, Pietro ^a   Pearl, Frances ^c  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Bioinformatics; Cluster analysis; Cytokines; Early genes; EGR2; Neuroprotection; Repair; Tissue protection

Indexed keywords

ALPHA1 INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 2; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P35; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEPTIN; LEUKEMIA INHIBITORY FACTOR; NERVE GROWTH FACTOR; ONCOSTATIN M; PROLACTIN; STEM CELL FACTOR; THROMBOPOIETIN; TISSUE PROTECTIVE CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; BIOINFORMATICS; CLUSTER ANALYSIS; CONTROLLED STUDY; DATA PROCESSING; FEASIBILITY STUDY; GENE EXPRESSION; MYELINATION; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PILOT STUDY; PLASTICITY; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM; WOUND HEALING;

EID: 84897945252     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00115     Document Type: Article

References (25)

1. Oppenheim JJ. Cytokines: past, present, and future. Int J Hematol (2001) 74(1):3-8. doi: 10.1007/BF02982543
2. Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol (2010) 40(3):599-606. doi:10.1002/eji.201040319
3. Cerami A. The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. J Intern Med (2011) 269(1):8-15. doi:10.1111/j.1365-2796.2010.02319.x
4. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A (2000) 97(19):10526-31. doi:10.1073/pnas.97.19.10526
5. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ (2004) 11:S37-44. doi:10.1038/sj.cdd.4401450
6. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 264(5):405-32. doi:10.1111/j.1365-2796.2008.02024.x
7. Muhl H, Scheiermann P, Bachmann M, Hardle L, Heinrichs A, Pfeilschifter J. IL-22 in tissue-protective therapy. Br J Pharmacol (2013) 169(4):761-71. doi:10.1111/bph.12196
8. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 305(5681):239-42. doi:10.1126/science.1098313
9. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 105(31):10925-30. doi:10.1073/pnas.0805594105
10. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med (2000) 342(18):1350-8. doi:10.1056/NEJM200005043421807
11. Haggiag S, Zhang PL, Slutzky G, Shinder V, Kumar A, Chebath J, et al. Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor-interleukin-6 chimera. J Neurosci Res (2001) 64(6):564-74. doi:10.1002/jnr.1108
12. Mengozzi M, Cervellini I, Villa P, Erbayraktar Z, Gokmen N, Yilmaz O, et al. Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke. Proc Natl Acad Sci U S A (2012) 109(24):9617-22. doi:10.1073/pnas.1200554109
13. Cervellini I, Annenkov A, Brenton T, Chernajovsky Y, Ghezzi P, Mengozzi M. Erythropoietin (EPO) increases myelin gene expression in CG4 oligodendrocyte cells through the classical EPO receptor. Mol Med (2013) 19:223-9. doi:10.2119/molmed.2013.00013
14. Duarte RF, Franf DA. The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance. Leuk Lymphoma (2002) 43(6):1179-87. doi:10.1080/10428190290026231
15. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood (2003) 102(4):1340-6. doi:10.1182/blood-2003-01-0223
16. Ghezzi P, Conklin D. Tissue-protective cytokines: structure and evolution. Methods Mol Biol (2013) 982:43-58. doi:10.1007/978-1-62703-308-4_3
17. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res (2011) 39:D561-8. doi:10.1093/nar/gkq973
18. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 4(1):44-57. doi:10.1038/nprot.2008.211
19. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med (2002) 8(6):613-9. doi:10.1038/nm0602-613
20. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL, et al. Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci (2006) 26(47):12174-85. doi:10.1523/JNEUROSCI.2289-06.2006
21. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet (1998) 18(4):382-4. doi:10.1038/ng0498-382
22. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev (1998) 28(3):370-490. doi:10.1016/S0165-0173(98)00018-6
23. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 2(9):647-56. doi:10.1038/nrc883
24. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A (2004) 101(26):9855-60. doi:10.1073/pnas.0403172101
25. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1995) 92(13):6190-4. doi:10.1073/pnas.92.13.6190